Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OS Therapies Inc OSTX

Healthcare Biotechnology
OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the... see more

Recent & Breaking News (NYSEAM:OSTX)

    OS Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update

    Business Wire 6 days ago

    OS Therapies to Present at The Spartan Capital Investor Conference

    Business Wire November 4, 2024

    Join OS Therapies' Exclusive Live Investor Webinar and Q&A Session on October 30

    Business Wire October 30, 2024

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Business Wire October 28, 2024

    OS Therapies to Present at the LD Micro Main Event XVII

    Business Wire October 24, 2024

    OS Therapies to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit

    Business Wire October 17, 2024

    OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Completes Last Patient Visit

    Business Wire October 3, 2024

    OS Therapies Announces Development of Two Novel Tunable Antibody Drug Conjugate (tADC)-Based Therapeutic Candidates

    Business Wire September 13, 2024

    OS Therapies Announces Positive Efficacy and Safety Data for Ovarian Cancer Therapeutic Candidate Developed Based on Tunable Antibody Drug Conjugate (tADC) Platform Using Proprietary Silicone Linker Platform in Preclinical Models

    Accesswire September 11, 2024

    OS Therapies to Present at H.C. Wainright 26th Annual Global Investment Conference

    Business Wire September 5, 2024

    OS Therapies Announces Last Patient Enrolled in OST-HER2 Osteosarcoma Phase 2b Clinical Trial Receives Last Treatment Dose

    Business Wire August 29, 2024

    OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board

    Business Wire August 22, 2024

    OS Therapies Clarifies CUSIP of Common Stock

    Business Wire August 22, 2024

    OS Therapies Accepted Into Johnson & Johnson Innovation - JLABS

    Business Wire August 19, 2024

    OS Therapies Reports Second Quarter 2024 Financial Results

    Accesswire August 15, 2024

    OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    Accesswire August 9, 2024

    OS Therapies Announces Osteosarcoma Scientific and Medical Advisory Board

    Accesswire August 6, 2024

    OS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol "OSTX"

    Business Wire July 31, 2024

    OS Therapies Announces Positive Safety Data from Phase 1 Clinical Trial of OST-HER2 in HER2-Expressing Breast Cancer and in Preclinical Efficacy in Models of Breast Cancer

    Business Wire July 24, 2024

    OS Therapies Announces Positive Clinical Update from Ongoing Phase 2b Clinical Trial in Resected, Recurrent Osteosarcoma

    Business Wire June 3, 2024